```html

Jaundice in Adults – A Complete Medical Guide

Overview

Jaundice (medical term: icterus) is a visible yellowing of the skin, sclerae (the whites of the eyes), and mucous membranes caused by an accumulation of bilirubin in the bloodstream. Bilirubin is a yellow‑orange pigment produced when red blood cells break down. In healthy adults, the liver processes bilirubin, turning it water‑soluble so it can be eliminated in bile and stool.

Although jaundice is most commonly associated with infants, it is also a frequent sign of underlying disease in adults. In the United States, about 1–2 % of hospital admissions involve a patient presenting with jaundice, and it accounts for roughly 5–10 % of emergency department visits for abdominal complaints.

Adults of any age can develop jaundice, but the risk increases with:

• Chronic liver disease (e.g., hepatitis B or C, alcoholic liver disease, non‑alcoholic fatty liver disease)
• Age > 50 years
• Heavy alcohol consumption
• Obesity and metabolic syndrome
• History of gallstones or pancreatic disease

Symptoms

Jaundice itself is a symptom, not a disease. The following signs and associated symptoms help clinicians pinpoint the underlying cause.

Visible Signs

• Yellow skin – often first noticed on the face and neck, later spreading to the trunk and extremities.
• Yellow sclerae – the most reliable early sign because the sclerae cannot be masked by makeup or skin tone.
• Dark urine – bilirubin excreted by the kidneys gives urine a tea‑colored appearance.
• Pale, clay‑colored stool – lack of bile pigments in the gastrointestinal tract.
• Pruritus (itching) – due to deposition of bile salts in the skin.

Systemic Symptoms

• Fatigue and generalized weakness
• Abdominal discomfort (especially in the right upper quadrant)
• Loss of appetite, nausea, or vomiting
• Weight loss (unexplained)
• Fever or chills (if infection is present)
• Upper back or shoulder pain – may indicate pancreatic involvement.

When Bilirubin Levels Are Very High

• Confusion, disorientation, or difficulty concentrating (“bilirubin encephalopathy” – rare in adults but serious)
• Rapid heart rate and low blood pressure (sign of sepsis or severe liver failure)

Causes and Risk Factors

Jaundice results when the balance between bilirubin production and elimination is disturbed. The pathophysiology is divided into three broad categories.

Pre‑Hepatic (Hemolytic) Causes

• Hemolysis – accelerated breakdown of red blood cells (e.g., autoimmune hemolytic anemia, hereditary spherocytosis, sickle cell disease).
• Mechanical destruction – prosthetic heart valves or severe burns.
• Medications that cause hemolysis (e.g., high‑dose penicillins, quinine).

Hepatic (Parenchymal) Causes

• Viral hepatitis (B, C, D, and less commonly A/E)
• Alcoholic hepatitis and cirrhosis
• Non‑alcoholic fatty liver disease (NAFLD) / non‑alcoholic steatohepatitis (NASH)
• Drug‑induced liver injury (acetaminophen overdose, isoniazid, methotrexate)
• Autoimmune hepatitis
• Genetic disorders (e.g., Gilbert syndrome, Crigler‑Najjar, Dubin‑Johnson)

Post‑Hepatic (Obstructive) Causes

• Gallstones blocking the common bile duct (choledocholithiasis)
• Pancreatic head carcinoma or pancreatic cysts compressing the biliary tract
• Strictures from prior surgeries or chronic pancreatitis
• Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)
• Cholangiocarcinoma (bile‑duct cancer)

Risk Factors

Factor	Why It Increases Risk
Heavy alcohol use	Liver inflammation and fibrosis impair bilirubin processing.
Obesity & metabolic syndrome	Promotes NAFLD/NASH, a leading cause of adult jaundice.
Chronic viral hepatitis	Persistent liver injury reduces functional hepatocytes.
Family history of hereditary bilirubin disorders	Genetic mutations affect bilirubin conjugation or excretion.
Previous gallstone disease or biliary surgery	Scarring or residual stones may block bile flow.

Diagnosis

Diagnosing jaundice involves confirming elevated bilirubin and identifying the site of the problem.

Initial Laboratory Evaluation

• Total bilirubin – normal 0.3–1.2 mg/dL; levels > 2.5 mg/dL usually produce visible yellowing.
• Direct (conjugated) vs. indirect (unconjugated) bilirubin – distinguishes pre‑hepatic (high indirect) from hepatic/post‑hepatic (high direct) causes.
• Liver function panel – ALT, AST, alkaline phosphatase (ALP), gamma‑glutamyl transferase (GGT), and albumin.
• Complete blood count (CBC) – looks for anemia or leukocytosis.
• Coagulation profile (PT/INR) – assesses liver synthetic function.

Imaging Studies

• Abdominal ultrasound – first‑line; evaluates gallstones, bile‑duct dilation, liver texture.
• CT scan or MRI/MRCP (magnetic resonance cholangiopancreatography) – detailed view of pancreatic masses, biliary strictures, or metastatic disease.
• Endoscopic ultrasound (EUS) and ERCP (endoscopic retrograde cholangiopancreatography) – diagnostic and therapeutic (e.g., stone removal, stent placement).

Specialized Tests

• Serologic tests for viral hepatitis (HBsAg, anti‑HBc, HCV RNA).
• Autoimmune markers – ANA, ASMA, anti‑LKM‑1 for autoimmune hepatitis; AMA for primary biliary cholangitis.
• Hemolysis work‑up – haptoglobin, LDH, reticulocyte count, peripheral smear.
• Liver biopsy – reserved for unclear cases or when specific histology will guide therapy.

Diagnostic Algorithm (Simplified)

1. Confirm elevated bilirubin → Determine direct vs. indirect.
2. If indirect >> direct → Look for hemolysis (CBC, haptoglobin, smear).
3. If direct elevated → Perform liver panel + abdominal ultrasound.
4. Ultrasound shows ductal dilation? → Consider obstructive cause → MRCP/ERCP.
5. No dilation → Evaluate hepatic causes → Viral serologies, auto‑immune panel, metabolic work‑up.

Treatment Options

Treatment targets the underlying cause; bilirubin levels usually improve once the primary disease is controlled.

Pre‑Hepatic (Hemolytic) Jaundice

• Treat the trigger – discontinue offending drugs, manage autoimmune hemolysis with steroids or rituximab.
• Blood transfusions in severe anemia.
• Folate supplementation to support erythropoiesis.

Hepatic Jaundice

• Viral hepatitis – antiviral regimens (e.g., sofosbuvir/ledipasvir for HCV, entecavir or tenofovir for HBV).
• Alcoholic liver disease – alcohol cessation, nutritional support, corticosteroids for severe alcoholic hepatitis (per Lille score).
• NAFLD/NASH – weight loss (≥ 7‑10 % body weight), diabetes control, vitamin E (in non‑diabetic patients), consider pioglitazone.
• Drug‑induced injury – immediate discontinuation of the culprit; N‑acetylcysteine for acetaminophen toxicity.
• Autoimmune hepatitis – high‑dose prednisone followed by azathioprine.

Post‑Hepatic (Obstructive) Jaundice

• Endoscopic stone extraction (ERCP) – first‑line for choledocholithiasis.
• Biliary stenting – relieves malignant obstruction; often combined with chemotherapy.
• Surgical bypass (e.g., hepaticojejunostomy) – for unresectable tumors or complex strictures.
• Radiation or targeted therapy – for cholangiocarcinoma or pancreatic cancer.

Supportive Care

• Hydration and electrolytes – especially if vomiting or diuretics are used.
• Pruritus relief – cholestyramine, rifampin, or sertraline.
• Phototherapy – rarely used in adults, reserved for extreme hyperbilirubinemia (> 30 mg/dL) to prevent neurologic toxicity.
• Vitamin K supplementation if coagulopathy develops.

Living with Jaundice (Adult)

Even after the acute episode resolves, many patients need ongoing management.

Daily Lifestyle Tips

1. Nutrition – Small, low‑fat meals; avoid raw seafood and unpasteurized dairy if liver function is compromised. Incorporate high‑protein foods (lean meat, beans) to support regeneration.
2. Hydration – Aim for 2‑3 L of water daily unless fluid‑restricted by ascites.
3. Alcohol abstinence – Zero tolerance is recommended for most liver diseases.
4. Weight management – For NAFLD/NASH, gradual weight loss of 0.5–1 kg/week improves liver enzymes and bilirubin.
5. Medication review – Keep a current list; avoid over‑the‑counter acetaminophen > 2 g/day and herbal supplements with unknown hepatotoxicity.
6. Vaccinations – Hepatitis A and B vaccinations if not immune; annual flu shot and COVID‑19 booster per CDC guidelines.
7. Sun protection – Skin may be more sensitive; use SPF 30+.

Monitoring

• Lab check‑ups: bilirubin, ALT/AST, ALP, INR every 3–6 months (or as directed).
• Imaging: ultrasound annually for cirrhosis surveillance; more often if gallstones or biliary disease are present.
• Screen for hepatocellular carcinoma (HCC) with ultrasound + AFP every 6 months in cirrhotic patients.

Prevention

Because jaundice is a symptom, preventing it means reducing the risk of the underlying diseases.

• Vaccinate against hepatitis A and B.
• Practice safe sex and avoid sharing needles to reduce viral hepatitis transmission.
• Limit alcohol intake to ≤ 1 drink/day for women and ≤ 2 drinks/day for men.
• Maintain a healthy weight (BMI 18.5–24.9) and engage in ≥ 150 minutes of moderate‑intensity aerobic activity weekly.
• Choose a balanced diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids; limit saturated fats and refined sugars.
• Use medications responsibly; follow dosing instructions and discuss liver‑risk drugs with a clinician.
• Promptly treat gallstone disease and monitor for biliary symptoms.

Complications

If the underlying cause of jaundice is not addressed, serious complications can arise:

• Acute liver failure – rapid loss of liver function; may require transplantation.
• Chronic cirrhosis – portal hypertension, ascites, variceal bleeding.
• Hepatorenal syndrome – kidney dysfunction secondary to severe liver disease.
• Hepatocellular carcinoma – risk is 1‑4 % per year in cirrhotic patients.
• Cholestatic pruritus – severely affects quality of life and can lead to skin breakdown.
• Coagulopathy and bleeding – due to reduced production of clotting factors.
• Neurologic toxicity – bilirubin‑induced encephalopathy, though rare in adults.

When to Seek Emergency Care

References

1. Mayo Clinic. Jaundice. https://www.mayoclinic.org/diseases-conditions/jaundice/symptoms-causes/syc-20373791 (accessed May 2026).
2. CDC. Hepatitis B and C Statistics. https://www.cdc.gov/hepatitis/statistics (accessed May 2026).
3. NIH National Institute of Diabetes and Digestive and Kidney Diseases. Non‑Alcoholic Fatty Liver Disease. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash (accessed May 2026).
4. World Health Organization. Guidelines on Prevention and Treatment of Viral Hepatitis. 2023 edition. https://www.who.int/publications/i/item/WHO‑Hepatitis‑2023 (accessed May 2026).
5. Cleveland Clinic. Obstructive Jaundice: Diagnosis and Management. https://my.clevelandclinic.org/health/diseases/15646-obstructive-jaundice (accessed May 2026).
6. American Association for the Study of Liver Diseases (AASLD). Practice Guidance on the Management of Hepatocellular Carcinoma. 2024. https://www.aasld.org (accessed May 2026).

```